Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus Article

Soria-Juan, Barbara, Escacena, Natalia, Capilla-Gonzalez, Vivian et al. (2019). Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus . FRONTIERS IN IMMUNOLOGY, 10 10.3389/fimmu.2019.01151

Open Access International Collaboration

cited authors

  • Soria-Juan, Barbara; Escacena, Natalia; Capilla-Gonzalez, Vivian; Aguilera, Yolanda; Llanos, Lucia; Tejedo, Juan R; Bedoya, Francisco J; Juan, Veronica; De la Cuesta, Antonio; Ruiz-Salmeron, Rafael; Andreu, Enrique; Grochowicz, Lukas; Prosper, Felipe; Sanchez-Guijo, Fermin; Lozano, Francisco S; Miralles, Manuel; Del Rio-Sola, Lourdes; Castellanos, Gregorio; Moraleda, Jose M; Sackstein, Robert; Garcia-Arranz, Mariano; Garcia-Olmo, Damian; Martin, Franz; Hmadcha, Abdelkrim; Soria, Bernat

sustainable development goals

authors

publication date

  • June 4, 2019

webpage

published in

keywords

  • ADIPOSE-TISSUE
  • AUTOLOGOUS TRANSPLANTATION
  • BONE-MARROW
  • ENDOTHELIAL PROGENITOR CELLS
  • INTERNATIONAL-SOCIETY
  • INTRAARTERIAL INFUSION
  • Immunology
  • Life Sciences & Biomedicine
  • MARROW MONONUCLEAR-CELLS
  • MESENCHYMAL STEM-CELLS
  • PERIPHERAL ARTERIAL-DISEASE
  • STROMAL CELLS
  • Science & Technology
  • cell-based therapy
  • cellular medicaments
  • clinical trials
  • cost-effective
  • critical limb ischemia
  • diabetes

Digital Object Identifier (DOI)

publisher

  • FRONTIERS MEDIA SA

volume

  • 10